Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells

被引:80
作者
Lapointe, J
Fournier, A
Richard, V
Labrie, C
机构
[1] CHU Laval, Res Ctr, Mol Endocrinol Lab, Ste Foy, PQ G1V 4G2, Canada
[2] Univ Laval, Ste Foy, PQ G1V 4G2, Canada
关键词
D O I
10.1210/en.140.1.416
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although a large proportion of primary human breast cancers express the androgen receptor, and treatment with androgens exerts beneficial effects in women with breast cancer, the role and especially the mechanism of action of androgens in breast cancer development and growth are not well understood. The potential effect of androgens on bcl-2 protooncogene expression was investigated in a human breast cancer cell line whose proliferation is known to be inhibited by androgens. The estrogen-responsive ZR-75-1 cells were grown in the presence or absence of 5 alpha-dihydrotestosterone (DHT), alone or in combination with 17 beta-estradiol. DHT caused a marked down-regulation of Bcl-2 protein and messenger RNA levels in both the presence and absence of 17 beta-estradiol. The inhibitory effect of DHT was completely prevented by coincubation with the pure antiandrogen hydroxyflutamide. The present data indicate that androgens can downregulate bcl-2 protooncogene levels via an androgen receptor-mediated mechanism, thus providing a novel mechanism for their known inhibitory effect on breast cancer cell growth.
引用
收藏
页码:416 / 421
页数:6
相关论文
共 48 条
[1]  
BERCHEM GJ, 1995, CANCER RES, V55, P735
[2]  
BHARGAVA V, 1994, AM J PATHOL, V145, P535
[3]   POTENT STIMULATORY EFFECT OF INTERLEUKIN-1-ALPHA ON APOLIPOPROTEIN-D AND GROSS CYSTIC-DISEASE FLUID PROTEIN-15 EXPRESSION IN HUMAN BREAST-CANCER CELLS [J].
BLAIS, Y ;
SUGIMOTO, K ;
CARRIERE, MC ;
HAAGENSEN, DE ;
LABRIE, F ;
SIMARD, J .
INTERNATIONAL JOURNAL OF CANCER, 1994, 59 (03) :400-407
[4]  
BRYAN RM, 1984, CANCER, V54, P2436, DOI 10.1002/1097-0142(19841201)54:11<2436::AID-CNCR2820541121>3.0.CO
[5]  
2-H
[6]  
DAUVOIS S, 1991, CANCER RES, V51, P3131
[7]  
DELAUNOIT Y, 1991, CANCER RES, V51, P2797
[8]  
Dorai T, 1997, ANTICANCER RES, V17, P3307
[10]  
GOLDENBERG IS, 1964, JAMA-J AM MED ASSOC, V188, P1069